Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Day One Biopharmaceuticals (DAWN) Net Cash Flow (2022 - 2025)

Historic Net Cash Flow for Day One Biopharmaceuticals (DAWN) over the last 4 years, with Q3 2025 value amounting to $7.7 million.

  • Day One Biopharmaceuticals' Net Cash Flow fell 9582.03% to $7.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$379.5 million, marking a year-over-year decrease of 30898.53%. This contributed to the annual value of -$105.8 million for FY2024, which is 17271.48% down from last year.
  • Latest data reveals that Day One Biopharmaceuticals reported Net Cash Flow of $7.7 million as of Q3 2025, which was down 9582.03% from $2.3 million recorded in Q2 2025.
  • Over the past 5 years, Day One Biopharmaceuticals' Net Cash Flow peaked at $183.1 million during Q3 2024, and registered a low of -$297.8 million during Q4 2024.
  • For the 4-year period, Day One Biopharmaceuticals' Net Cash Flow averaged around -$16.1 million, with its median value being -$10.4 million (2023).
  • Data for Day One Biopharmaceuticals' Net Cash Flow shows a peak YoY increase of 25242.65% (in 2024) and a maximum YoY decrease of 276481.0% (in 2024) over the last 5 years.
  • Day One Biopharmaceuticals' Net Cash Flow (Quarter) stood at -$35.6 million in 2022, then soared by 70.8% to -$10.4 million in 2023, then tumbled by 2764.81% to -$297.8 million in 2024, then surged by 102.57% to $7.7 million in 2025.
  • Its Net Cash Flow stands at $7.7 million for Q3 2025, versus $2.3 million for Q2 2025 and -$91.6 million for Q1 2025.